Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

Y0001008

Citalopram -hydrobromid

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

1-[3-(Dimethylamino)-propyl]-1-(4-fluorphenyl)-1,3-dihydro-5-isobenzofurancarbonitril -hydrobromid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C20H21FN2O · HBr
CAS-Nummer:
59729-32-7
Molekulargewicht:
405.30
MDL-Nummer:
MFCD02101306
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329831217
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

citalopram

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

Br[H].CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3

InChI

1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H

InChIKey

WIHMBLDNRMIGDW-UHFFFAOYSA-N

Angaben zum Gen

human ... SLC6A4(6532)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Citalopram hydrobromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Wirksamer und selektiver Serotonin-Aufnahme-Hemmer (Ki = 5.4 nM); Antidepressivum

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1134233

Citalopram -hydrobromid, United States Pharmacopeia (USP) Reference Standard

1134244

Citalopram-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1134222

Citalopram-verwandte Verbindung H, United States Pharmacopeia (USP) Reference Standard

1134197

Citalopram-verwandte Verbindung G, United States Pharmacopeia (USP) Reference Standard

1134288

Citalopram-verwandte Verbindung E, United States Pharmacopeia (USP) Reference Standard

1134266

Citalopram-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

1134255

Citalopram-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1134277

Citalopram-verwandte Verbindung D, United States Pharmacopeia (USP) Reference Standard

1134299

Citalopram-verwandte Verbindung F, United States Pharmacopeia (USP) Reference Standard

Y0000855

Citalopram für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

Y0001007

Citalopram -hydrochlorid, European Pharmacopoeia (EP) Reference Standard

1134142

R-Citalopramoxalat, United States Pharmacopeia (USP) Reference Standard

PHR1906

5-Brom-1-(4-fluorphenyl)-1,3-dihydro-N,N-dimethyl-1-isobenzofuranpropanamin -hydrobromid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1863

(RS)-Dimethyl-(1-methyl-3,3-diphenyl-allyl)-amin -hydrochlorid, Pharmaceutical Secondary Standard; Certified Reference Material

BP1153

Citalopram -hydrobromid, British Pharmacopoeia (BP) Reference Standard

PHR1905

Citalopram-verwandte Verbindung G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1901

Citalopram-verwandte Verbindung A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1154

Citalopram-Unreinheit Standard, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Health hazardExclamation mark
GHS08,GHS07

Signalwort

Warning

Gefahreneinstufungen

Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - STOT SE 3

Zielorgane

Central nervous system

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Yevheniia Mikheenko et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(6), 1395-1404 (2015-01-15)
Trait anxiety is a risk factor for the development and maintenance of affective disorders, and insights into the underlying brain mechanisms are vital for improving treatment and prevention strategies. Translational studies in non-human primates, where targeted neurochemical and genetic manipulations
Gordon F Buchanan et al.
The Journal of physiology, 592(19), 4395-4410 (2014-08-12)
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in patients with refractory epilepsy. Defects in central control of breathing are important contributors to the pathophysiology of SUDEP, and serotonin (5-HT) system dysfunction may be involved. Here
M D Opal et al.
Molecular psychiatry, 19(10), 1106-1114 (2013-10-30)
Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert antidepressant actions with a faster-onset (5 days) than that of current antidepressants (14 days) in mice. Subchronic (5 days)
Jesper T Andreasen et al.
Brain research, 1601, 117-126 (2015-01-13)
Depression and anxiety often co-occur, and conventional monoamine-facilitating antidepressants show efficacy against symptoms in both disorders. Rodent studies indicate that antidepressant effects of monoamine-based antidepressants involve increased α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid glutamate receptor (AMPAR) neurotransmission, and positive allosteric modulators (PAMs) at
Laura Jiménez-Sánchez et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(11), 2673-2680 (2014-05-30)
Paradoxically, N-methyl-D-aspartate (NMDA) receptor antagonists are used to model certain aspects of schizophrenia as well as to treat refractory depression. However, the role of different subunits of the NMDA receptor in both conditions is poorly understood. Here we used biochemical
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.